SAXAGLIPTIN HYDROCHLORIDE | A205994 | GLENMARK PHARMACEUTICALS LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
AstraZeneca AB v. Glenmark Generics Ltd. et al 2 patentsANDA 205994saxagliptin hydrochloride | D. Del. | 2014-05-23 | Terminated 2015-04-14 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$1.18
per ea
Lowest NADAC/Unit
$1.12
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 68462072630SAXAGLIPTIN HCL 2.5 MG TABLET | $1.18 | EA | Generic | — | 2026-06-17 |
| 68462072690SAXAGLIPTIN HCL 2.5 MG TABLET | $1.18 | EA | Generic | — | 2026-06-17 |
| 68462072730SAXAGLIPTIN HCL 5 MG TABLET | $1.12 | EA | Generic | — | 2026-06-17 |
| 68462072790SAXAGLIPTIN HCL 5 MG TABLET | $1.12 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.